home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  August 17, 2017
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 588 active entries



Phone: +33 473 44 94 30
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


Neuronax is a biotechnological company focused on the development and discovery of new candidate-drugs for neural repair in cases of traumatic or degenerative disorders of the nervous system. The company focuses particular affections for which the capacities to treat patients are limited and the "unmet needs" are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function.

Our most advanced product, NX210, which has demonstrated a combined efficacy with neuro-protective and neuro-regenerative activities, is a promising first-in-class candidate that may treat various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Multiple Sclerosis, Alzheimer or Parkinson’s diseases.

A program of preclinical regulatory studies has been completed for this candidate and no apparent toxicity was observed. Thus, IND filing and Phase I/II study in spinal cord injuries is expected to next year.

NEURONAX has developed a cellular platform combining various biological models of nervous cells dedicated to cell-based screening and provides its expertise for evaluation of the effect of an active principle for the nervous system. More recently, expertise of NEURONAX was expanded with the development of specific programs in the regenerative medicine area. Thus, through academic and private collaborations, we are optimizing research grade or clinical grade protocols to expand or differentiate adult stem cells and we are collaborating in preclinical development of particular cell-based therapy.


Selected Categories:
Product Company   Service Company
- General
- Research
- Research
- Research
- Research
- Research
- Services

Last update of this entry: June 10, 2014

Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.